DOSE ESCALATION IN ACCELERATED HYPERFRACTIONATION FOR ADVANCED HEAD AND NECK CANCER
HUSSAIN MOHAMED OMAR;
Abstract
The present study includes 50 untreated patients with locally advanced head and neck squamous cell carcinoma, referred to Kasr El-Eini Center of Radiation Oncology and Nuclear Medicine (NEMROCK), from February 1994 till February 1996.
All patients received the following radiotherapy escalating schedule:
1. 2 Gy BID 2 weeks 24 Gy
1. 4 Gy BID 2 weeks
28 Gy
1.6 Gy BID 1.5 weeks 22.4 Gy
74.4 Gy
Total 74.4 Gy in 54 fractions and 37 days. Booster doses could be given if clinical residual would be noticed with maximum dose 80.8 Gy.
The rationale of hyperfractionation is to allow for increasing the total dose given for better tumor control while increasing late reacting normal tissue tolerance by decreasing the dose per fraction. For better tumor control with improvement of early and late normal tissue tolerance we combine feature of
All patients received the following radiotherapy escalating schedule:
1. 2 Gy BID 2 weeks 24 Gy
1. 4 Gy BID 2 weeks
28 Gy
1.6 Gy BID 1.5 weeks 22.4 Gy
74.4 Gy
Total 74.4 Gy in 54 fractions and 37 days. Booster doses could be given if clinical residual would be noticed with maximum dose 80.8 Gy.
The rationale of hyperfractionation is to allow for increasing the total dose given for better tumor control while increasing late reacting normal tissue tolerance by decreasing the dose per fraction. For better tumor control with improvement of early and late normal tissue tolerance we combine feature of
Other data
| Title | DOSE ESCALATION IN ACCELERATED HYPERFRACTIONATION FOR ADVANCED HEAD AND NECK CANCER | Other Titles | التدرج التصاعدى لجرعات العلاج الاشعاعى المكثف فى اورام الرأس والعنق المتقدمة | Authors | HUSSAIN MOHAMED OMAR | Issue Date | 1996 |
Attached Files
| File | Size | Format | |
|---|---|---|---|
| B14145.pdf | 950.21 kB | Adobe PDF | View/Open |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.